Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,125 | 267 | 1,844 |
| Samples | 538 | 101 | 431 |
| Peptides | 417 | 73 | 352 |
Function
PTK2B · Protein tyrosine kinase 2 beta
This gene encodes a cytoplasmic protein tyrosine kinase which is involved in calcium-induced regulation of ion channels and activation of the map kinase signaling pathway. The encoded protein may represent an important signaling intermediate between neuropeptide-activated receptors or neurotransmitters that increase calcium flux and the downstream signals that regulate neuronal activity. The encoded protein undergoes rapid tyrosine phosphorylation and activation in response to increases in the intracellular calcium concentration, nicotinic acetylcholine receptor activation, membrane depolarization, or protein kinase C activation. This protein has been shown to bind CRK-associated substrate, nephrocystin, GTPase regulator associated with FAK, and the SH2 domain of GRB2. The encoded protein is a member of the FAK subfamily of protein tyrosine kinases but lacks significant sequence similarity to kinases from other subfamilies. Four transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 409 amino-acid changes on canonical ENST00000346049 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PTK2B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PTK2B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Glioblastoma | 6/98 6% | 0/0 0% |
| Endometrial Carcinoma | 9/42 21% | 26/612 4% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| Melanoma | 12/210 6% | 69/1899 4% |
| Colorectal Carcinoma | 16/143 11% | 67/3239 2% |
| Mesothelioma | 2/62 3% | 3/165 2% |
| Gastric Carcinoma | 3/74 4% | 34/1809 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Ewings Sarcoma | 3/63 5% | 3/262 1% |
| Non-Small Cell Lung Carcinoma | 7/304 2% | 23/1390 2% |
| Burkitts Lymphoma | 3/32 9% | 1/196 1% |
| Cervical Carcinoma | 0/35 0% | 6/422 1% |
| Bladder Carcinoma | 2/58 3% | 10/956 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 9/752 1% |
| Other Solid Cancers | 3/94 3% | 16/1515 1% |
| Esophageal Carcinoma | 0/23 0% | 8/769 1% |
| Ovarian Carcinoma | 0/109 0% | 11/998 1% |
| Neuroendocrine Tumour | 4/154 3% | 3/577 1% |
| Other Sarcomas | 1/69 1% | 6/699 1% |
| Hepatocellular Carcinoma | 0/46 0% | 20/2210 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 20/2550 1% |
| Biliary Tract Carcinoma | 0/54 0% | 8/950 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Breast Carcinoma | 6/144 4% | 18/3264 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 5/810 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 10/1592 1% |
| Prostate Carcinoma | 3/13 23% | 10/2105 0% |
| Glioma | 0/52 0% | 13/2127 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
Mutation Distribution
Where PTK2B is mutated · all tissues, split by cell line vs tissue
How many mutations in PTK2B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,125 mutations in PTK2B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|